share_log

424B3: Prospectus

424B3: Prospectus

424B3：募資說明書
美股SEC公告 ·  06/27 20:22
牛牛AI助理已提取核心訊息
NeuroSense Therapeutics has filed a prospectus supplement on June 27, 2024, to update and amend its previous prospectus dated May 22, 2024. This supplement includes information from the company's Report on Form 6-K submitted to the SEC on the same date. The supplement details amendments to warrants issued to an institutional investor, extending the termination date of warrants from 2023 and 2024 to October 12, 2029. The amendments also adjust the 'Redemption Right' in the 2023 Warrant. NeuroSense Therapeutics' ordinary shares and warrants are traded on the Nasdaq under the symbols 'NRSN' and 'NRSNW,' with closing prices on June 26, 2024, at $0.85 and $0.18 respectively. The company highlights the high degree of risk involved in investing in its securities and refers to the 'Risk Factors' section of the Prospectus for more details. The SEC, Israeli Securities Authority, nor any state securities commission has approved or disapproved the securities, nor have they confirmed the completeness or truthfulness of the Prospectus or this supplement.
NeuroSense Therapeutics has filed a prospectus supplement on June 27, 2024, to update and amend its previous prospectus dated May 22, 2024. This supplement includes information from the company's Report on Form 6-K submitted to the SEC on the same date. The supplement details amendments to warrants issued to an institutional investor, extending the termination date of warrants from 2023 and 2024 to October 12, 2029. The amendments also adjust the 'Redemption Right' in the 2023 Warrant. NeuroSense Therapeutics' ordinary shares and warrants are traded on the Nasdaq under the symbols 'NRSN' and 'NRSNW,' with closing prices on June 26, 2024, at $0.85 and $0.18 respectively. The company highlights the high degree of risk involved in investing in its securities and refers to the 'Risk Factors' section of the Prospectus for more details. The SEC, Israeli Securities Authority, nor any state securities commission has approved or disapproved the securities, nor have they confirmed the completeness or truthfulness of the Prospectus or this supplement.
NeuroSense Therapeutics於2024年6月27日提交了招股書補充，對其於2024年5月22日發佈的招股書進行更新和修改。此補充包括公司在同一日期提交給美國證券交易委員會的6-K表格中提供的信息。補充詳細說明了對發給機構投資者的認股權證的修正，將認股期限從2023年和2024年延長至2029年10月12日。修正還調整了2023年認股權證的“贖回權”。NeuroSense Therapeutics的普通股和認股權證在納斯達克交易，代碼爲“NRSN”和“NRSNW”，於2024年6月26日收盤價分別爲0.85美元和0.18美元。該公司強調投資其證券具有高風險，建議查閱招股書的“風險因素”部分以獲取更多細節信息。美國證券交易委員會、以色列證券管理機構或任何州證券委員會均未批准或否定證券，也未確認招股書或本補充的完整性或真實性。
NeuroSense Therapeutics於2024年6月27日提交了招股書補充，對其於2024年5月22日發佈的招股書進行更新和修改。此補充包括公司在同一日期提交給美國證券交易委員會的6-K表格中提供的信息。補充詳細說明了對發給機構投資者的認股權證的修正，將認股期限從2023年和2024年延長至2029年10月12日。修正還調整了2023年認股權證的“贖回權”。NeuroSense Therapeutics的普通股和認股權證在納斯達克交易，代碼爲“NRSN”和“NRSNW”，於2024年6月26日收盤價分別爲0.85美元和0.18美元。該公司強調投資其證券具有高風險，建議查閱招股書的“風險因素”部分以獲取更多細節信息。美國證券交易委員會、以色列證券管理機構或任何州證券委員會均未批准或否定證券，也未確認招股書或本補充的完整性或真實性。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。